CLINICAL TRIALS PROFILE FOR NICOTINE

505(b)(2) Clinical Trials for nicotine

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT00224419 ↗	Testing Pharmacological Therapies for Pregnant Smokers	Terminated	National Cancer Institute (NCI)	Phase 4	2003-06-01	Nicotine dependence has not been sufficiently addressed in current state-of-the-science cessation interventions for pregnant smokers. The weight of the evidence from the general population of smokers suggests that nicotine replacement therapies may be beneficial cessation aids for pregnant smokers who are unable to stop smoking. The tremendous potential of these therapies for promoting smoking cessation among pregnant women creates a pressing need for decision tools and protocols to encourage treatment adherence that is essential for rigorous evaluation of the effectiveness of OTC NRT when provided as part of prenatal care. The results of this research could be directly translated to the improvement of obstetrical care providers' clinical practices. Medically supervised use of OTC NRT by pregnant smokers is an alternative to continued smoking that has the potential to substantially increase rates of smoking cessation during pregnancy.
OTC	NCT00224419 ↗	Testing Pharmacological Therapies for Pregnant Smokers	Terminated	Duke University	Phase 4	2003-06-01	Nicotine dependence has not been sufficiently addressed in current state-of-the-science cessation interventions for pregnant smokers. The weight of the evidence from the general population of smokers suggests that nicotine replacement therapies may be beneficial cessation aids for pregnant smokers who are unable to stop smoking. The tremendous potential of these therapies for promoting smoking cessation among pregnant women creates a pressing need for decision tools and protocols to encourage treatment adherence that is essential for rigorous evaluation of the effectiveness of OTC NRT when provided as part of prenatal care. The results of this research could be directly translated to the improvement of obstetrical care providers' clinical practices. Medically supervised use of OTC NRT by pregnant smokers is an alternative to continued smoking that has the potential to substantially increase rates of smoking cessation during pregnancy.
OTC	NCT00405912 ↗	St. John's Wort for Tobacco Cessation	Completed	National Cancer Institute (NCI)	Phase 2	2005-09-01	After a steady decline for the last 50 years, the prevalence of tobacco use in the United States has reached a plateau of approximately 23%. Currently available treatments among adults are expensive and not efficacious for all tobacco users. New pharmacologic agents need to be developed and tested to achieve the Healthy People 2010 goal of less than a 12% adult tobacco use prevalence. Bupropion, an FDA approved agent for tobacco cessation, acts by inhibiting central synaptosomal reuptake of dopamine and norepinephrine. A widely used herbal antidepressant, St. John's Wort (SJW), shares a similar mechanism of action and is effective for treating mild to moderate depression. SJW is well tolerated, available over the counter, and is significantly less expensive than the established treatments for tobacco dependence. To date, no prospective clinical trial evaluating the efficacy of SJW for the treatment of tobacco use has been published. We propose to evaluate the efficacy of SJW for increasing tobacco abstinence and decreasing nicotine withdrawal symptoms in a randomized, double-blind, placebo-controlled, three-arm, parallel group, dose-ranging clinical trial. Participants (N=120) will be randomly assigned to one of the three groups and will receive a twelve-week course of SJW 900 mg per day, 1800 mg per day, or a matching placebo. This study is anticipated to provide the data needed to develop a larger randomized controlled clinical trial submitted through the R01 funding mechanism.
OTC	NCT00405912 ↗	St. John's Wort for Tobacco Cessation	Completed	Mayo Clinic	Phase 2	2005-09-01	After a steady decline for the last 50 years, the prevalence of tobacco use in the United States has reached a plateau of approximately 23%. Currently available treatments among adults are expensive and not efficacious for all tobacco users. New pharmacologic agents need to be developed and tested to achieve the Healthy People 2010 goal of less than a 12% adult tobacco use prevalence. Bupropion, an FDA approved agent for tobacco cessation, acts by inhibiting central synaptosomal reuptake of dopamine and norepinephrine. A widely used herbal antidepressant, St. John's Wort (SJW), shares a similar mechanism of action and is effective for treating mild to moderate depression. SJW is well tolerated, available over the counter, and is significantly less expensive than the established treatments for tobacco dependence. To date, no prospective clinical trial evaluating the efficacy of SJW for the treatment of tobacco use has been published. We propose to evaluate the efficacy of SJW for increasing tobacco abstinence and decreasing nicotine withdrawal symptoms in a randomized, double-blind, placebo-controlled, three-arm, parallel group, dose-ranging clinical trial. Participants (N=120) will be randomly assigned to one of the three groups and will receive a twelve-week course of SJW 900 mg per day, 1800 mg per day, or a matching placebo. This study is anticipated to provide the data needed to develop a larger randomized controlled clinical trial submitted through the R01 funding mechanism.
OTC	NCT00722124 ↗	S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence	Completed	Pharmavite	Phase 2/Phase 3	2008-09-01	Cigarette smoking is of great public health importance and is the single most important preventable cause of morbidity, mortality and excess health care costs in the United States. After a steady decline for the last 50 years, the prevalence of tobacco use in the United States has reached a plateau of approximately 21%. Currently available treatments among adults are not efficacious for all tobacco users. New pharmacologic agents thus need to be continually developed and tested. The release of dopamine in the nucleus accumbens is one of the key components of the pleasurable and rewarding effects of nicotine. Drugs that increase monoamine neurotransmitter availability (particularly dopamine and norepinephrine) are likely to increase the reward function and thus ameliorate withdrawal symptoms. S-Adenosyl-L-Methionine (SAMe), the primary methyl donor for the central nervous system (CNS), donates methyl groups towards presynaptic synthesis of CNS monoamine neurotransmitters. By facilitating the synthesis of dopamine and norepinephrine in the brain, SAMe is likely to ameliorate the symptoms of nicotine withdrawal, thus improving tobacco abstinence rates in smokers who are trying to stop smoking. SAMe is well tolerated and is available over-the-counter. To date, no prospective clinical trial evaluating the efficacy of SAMe for the treatment of tobacco dependence has been published. We propose to evaluate the efficacy of SAMe for increasing smoking abstinence and decreasing nicotine withdrawal symptoms in a randomized, blinded, placebo-controlled, three-arm, parallel-group, dose-ranging phase II clinical trial. Participants (N=120) will be randomly assigned to one of the three groups, and will receive an 8-week course of SAMe 800-mg per day, 1600-mg per day, or a matching placebo. This study is anticipated to provide the data needed to develop a larger randomized controlled clinical trial submitted through the R01 funding mechanism, if the results appear promising.
OTC	NCT00722124 ↗	S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence	Completed	Pharmavite LLC	Phase 2/Phase 3	2008-09-01	Cigarette smoking is of great public health importance and is the single most important preventable cause of morbidity, mortality and excess health care costs in the United States. After a steady decline for the last 50 years, the prevalence of tobacco use in the United States has reached a plateau of approximately 21%. Currently available treatments among adults are not efficacious for all tobacco users. New pharmacologic agents thus need to be continually developed and tested. The release of dopamine in the nucleus accumbens is one of the key components of the pleasurable and rewarding effects of nicotine. Drugs that increase monoamine neurotransmitter availability (particularly dopamine and norepinephrine) are likely to increase the reward function and thus ameliorate withdrawal symptoms. S-Adenosyl-L-Methionine (SAMe), the primary methyl donor for the central nervous system (CNS), donates methyl groups towards presynaptic synthesis of CNS monoamine neurotransmitters. By facilitating the synthesis of dopamine and norepinephrine in the brain, SAMe is likely to ameliorate the symptoms of nicotine withdrawal, thus improving tobacco abstinence rates in smokers who are trying to stop smoking. SAMe is well tolerated and is available over-the-counter. To date, no prospective clinical trial evaluating the efficacy of SAMe for the treatment of tobacco dependence has been published. We propose to evaluate the efficacy of SAMe for increasing smoking abstinence and decreasing nicotine withdrawal symptoms in a randomized, blinded, placebo-controlled, three-arm, parallel-group, dose-ranging phase II clinical trial. Participants (N=120) will be randomly assigned to one of the three groups, and will receive an 8-week course of SAMe 800-mg per day, 1600-mg per day, or a matching placebo. This study is anticipated to provide the data needed to develop a larger randomized controlled clinical trial submitted through the R01 funding mechanism, if the results appear promising.

All Clinical Trials for nicotine

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000284 ↗	Role of Metabolites in Nicotine Dependence (1) - 1	Completed	University of Minnesota	Phase 2	1995-02-01	The purpose of this study is to determine the effects of cotinine with or without a transdermal nicotine replacement on tobacco withdrawal symptoms.
NCT00000284 ↗	Role of Metabolites in Nicotine Dependence (1) - 1	Completed	University of Minnesota - Clinical and Translational Science Institute	Phase 2	1995-02-01	The purpose of this study is to determine the effects of cotinine with or without a transdermal nicotine replacement on tobacco withdrawal symptoms.
NCT00000284 ↗	Role of Metabolites in Nicotine Dependence (1) - 1	Completed	National Institute on Drug Abuse (NIDA)	Phase 2	1995-02-01	The purpose of this study is to determine the effects of cotinine with or without a transdermal nicotine replacement on tobacco withdrawal symptoms.
NCT00000288 ↗	Role of Metabolites in Nicotine Dependence (2) - 5	Completed	University of Minnesota	Phase 2	1995-12-01	The purpose of this study is to determine the effects of varying doses of cotinine on cigarette self-administration.
NCT00000288 ↗	Role of Metabolites in Nicotine Dependence (2) - 5	Completed	University of Minnesota - Clinical and Translational Science Institute	Phase 2	1995-12-01	The purpose of this study is to determine the effects of varying doses of cotinine on cigarette self-administration.
NCT00000288 ↗	Role of Metabolites in Nicotine Dependence (2) - 5	Completed	National Institute on Drug Abuse (NIDA)	Phase 2	1995-12-01	The purpose of this study is to determine the effects of varying doses of cotinine on cigarette self-administration.

Clinical Trial Conditions for nicotine

Condition Name

Condition Name for nicotine
Intervention	Trials
Smoking Cessation	215
Nicotine Dependence	147
Smoking	116
Tobacco Use Disorder	103

Condition MeSH

Condition MeSH for nicotine
Intervention	Trials
Tobacco Use Disorder	329
Schizophrenia	56
Alcoholism	41
Substance-Related Disorders	35

Clinical Trial Locations for nicotine

Trials by Country

Trials by Country for nicotine
Location	Trials
Canada	54
Sweden	29
France	26
Germany	18
China	15

Trials by US State

Trials by US State for nicotine
Location	Trials
California	95
Connecticut	74
Minnesota	66
Pennsylvania	65
North Carolina	63

Clinical Trial Progress for nicotine

Clinical Trial Phase

Clinical Trial Phase for nicotine
Clinical Trial Phase	Trials
PHASE4	20
PHASE3	3
PHASE2	8

Clinical Trial Status

Clinical Trial Status for nicotine
Clinical Trial Phase	Trials
Completed	626
Recruiting	119
Not yet recruiting	76

Clinical Trial Sponsors for nicotine

Sponsor Name

Sponsor Name for nicotine
Sponsor	Trials
National Institute on Drug Abuse (NIDA)	213
National Cancer Institute (NCI)	89
Yale University	61

Sponsor Type

Sponsor Type for nicotine
Sponsor	Trials
Other	1185
NIH	421
Industry	202

Last updated: July 26, 2026

Nicotine drug development update: clinical trials, market outlook, and exclusivity/projection by product type

Nicotine is not a single branded “drug” with one FDA sponsor; it is a therapeutic active ingredient delivered through multiple regulated products (NRT replacement therapies) and used across smoking-cessation and, in some markets, reduction/relapse-prevention indications. Market direction and clinical-trial activity are therefore best analyzed by delivery form and regulatory status (NRT vs non-NRT addiction pharmacotherapies that target nicotine pathways), plus geographic reimbursement dynamics.

Core takeaways

• Clinical activity concentrates in nicotine delivery-system optimization (faster onset, dose titration flexibility, combination regimens) rather than wholly new nicotine receptor pharmacology.
• Commercial outlook is driven by: (1) shift from prescription to OTC accessibility in key geographies, (2) payer and pharmacy shelf dynamics, (3) competition among patch, gum, lozenge, inhaler, and nasal spray, and (4) product differentiation through speed-of-relief and adherence.
• Projection hinges on adult smoking prevalence trends, cessation guideline uptake, and regulatory/policy settings (taxation, smoke-free measures, advertising restrictions).

Because “nicotine” spans multiple drug products and routes, any credible projection must be segmented by product type and regulatory category. No single consolidated FDA drug approval or Orange Book exclusivity construct applies to “nicotine” as a generic active ingredient across all delivery systems.

---

Which clinical trials for nicotine replacement therapy (NRT) are active and what are the main endpoints?

What trial questions typically look like in nicotine NRT Across nicotine delivery innovations, studies generally focus on:

• Abstinence outcomes: continuous abstinence and point prevalence at standard follow-up windows (commonly 4, 8, 12, 24, and 52 weeks in smoking-cessation trials).
• Time-to-peak nicotine exposure: faster delivery is used to address breakthrough cravings and improve adherence.
• Urge/craving scales: reduction in craving intensity and relief latency after dose.
• Safety/tolerability: adverse events, cardiovascular safety signals (especially in older cohorts), local tolerability (oral irritation with gum/lozenge, nasal irritation with spray, skin reactions with patches).
• Adherence and persistence: proportion using assigned regimen through planned duration.

Nicotine patch, gum, lozenge: what do recent trials typically test? (design patterns)

• Patch trials usually test dose titration logic and step-down schedules, sometimes with event-driven adjustments for missed cravings.
• Gum/lozenge trials commonly test chew-and-rest or dosing mechanics and formulation changes to improve nicotine bioavailability while reducing irritation.
• Combination NRT trials examine whether pairing a baseline patch with a rapid-acting NRT (gum/lozenge/inhaler/nasal spray) improves abstinence vs patch alone.

Nicotine inhaler and nasal spray: why trials remain active

• These forms target faster-onset craving control. Studies tend to compare:
  • onset and plasma nicotine kinetics,
  • craving relief over short intervals,
  • and tolerability versus oral NRT.

What “innovation” looks like clinically

Clinical development remains focused on:

• delivery kinetics (faster, smoother, less peak-trough variability),
• user experience (taste, texture, ease of use),
• dose flexibility (steering patients toward individualized dosing),
• and real-world adherence (switching patterns and persistence).

---

What is the current nicotine market size and growth outlook by product type (patch vs gum/lozenge vs inhaler vs nasal spray)?

Market structure Nicotine replacement therapy market demand is segmented by:

• Delivery form: transdermal patch, oral gum, oral lozenge, oral inhaler, nasal spray, and combination kits.
• Route-to-market: OTC vs prescription (varies by country).
• Channel: mass retail/pharmacy vs e-commerce vs healthcare systems.
• Regulatory framing: smoking cessation vs reduction/temporary abstinence support in some jurisdictions.

Patch remains a base regimen

Patches typically win on:

• adherence potential (low behavioral burden),
• stable baseline nicotine delivery,
• and cost effectiveness.

Growth tends to track:

• OTC availability expansion,
• and guideline-driven combination strategies.

Rapid-acting NRT expands with craving-management needs

Gum, lozenge, inhaler, and nasal spray benefit from:

• breakthrough craving coverage,
• clinician/payer encouragement of multi-product regimens,
• and consumer willingness to “stack” products when cravings spike.

Combination regimens are the swing factor for margins

Combination products often support:

• higher average selling prices,
• improved outcomes in cessation programs,
• and formulary inclusion in some healthcare systems.

---

When does nicotine product exclusivity end, and what are the patent/IP barriers to generic nicotine delivery systems?

IP is product- and formulation-specific Nicotine itself is an old, off-patent active ingredient in most jurisdictions. The enforceable exclusivity is typically in:

• formulation and delivery technologies (adhesive systems for patches, matrix designs, excipient blends, aerosol/nasal delivery mechanics),
• device components for inhalers,
• specific combination regimens (where patents exist),
• and sometimes method-of-use claims tied to dosing algorithms.

Practical exclusivity timeline reality

• Many “nicotine” products face early generic substitution because the API is widely available.
• The main barriers are not brand-level API exclusivity but local IP on formulation/device performance.

What changes the barrier profile

• New delivery kinetics: if a product claims superior onset, the IP estate may cover the specific kinetics-generating formulation approach.
• User-mechanics: patents on dosing procedures or user steps can survive longer than simple composition claims.
• Combination patents: some combination pack configurations and dosing schedules are protected.

---

How strong is the patent estate for nicotine delivery systems, and which patent types matter most?

Patent types that most often matter for nicotine

1. Formulation patents
   • patch adhesives and controlled release matrices,
   • oral nicotine matrices controlling dissolution and release,
   • nasal spray formulations affecting particle size distribution and mucosal absorption.
2. Device and delivery system patents
   • inhaler mouthpiece and aerosol generation,
   • nasal pump/actuator mechanisms if tied to specific performance.
3. Method-of-use patents
   • specific titration strategies,
   • combination regimen timing (patch plus rapid acting NRT),
   • and behavioral dosing guidance tied to a measurable endpoint.

Who typically holds relevant IP in nicotine NRT

Historically, the nicotine NRT portfolio has involved multiple multinational brands and line extensions. In practice, IP ownership changes with acquisitions and licensing, and country-by-country assignees matter.

Featured-snippet answer

For nicotine delivery systems, the enforceable IP estate is usually strongest in formulation/device patents rather than in the underlying nicotine molecule.

---

What FDA regulatory status applies to nicotine products (NRT vs non-nicotine smoking-cessation drugs)?

Regulatory framing

• Nicotine products are generally regulated as drug products for smoking cessation or temporary abstinence, using OTC and/or prescription pathways depending on jurisdiction and product.
• Non-nicotine smoking-cessation drugs (for comparison) include agents with distinct mechanisms (nicotinic modulation, dopamine/norepinephrine pathway modulation, etc.), but those are separate development programs and not “nicotine” products.

What matters for market projection

• OTC access expansion increases addressable market.
• Prescription restrictions and payer formulary inclusion shape reimbursement and pull-through.

---

Which competitive products are most likely to take share from nicotine NRT?

Main competitive vectors

1. Non-nicotine cessation pharmacotherapies
   • Compete on outcome efficacy, patient preference, and payer coverage.
2. Behavioral programs tied to reimbursement
   • Can affect effective conversion rates for NRT uptake.
3. Digital cessation tools integrated with pharmacotherapy
   • Often increase adherence to multi-week dosing regimens.
4. Alternative nicotine delivery formats
   • Less common but can disrupt substitution if they improve time-to-relief or user convenience.

Comparison logic

• NRT competes most strongly on:
  • safety profile and tolerability,
  • accessibility,
  • and ease of initiating therapy quickly.

---

What generic entry risks exist for nicotine products, and how do they affect pricing and forecasts?

Generic entry dynamics

• When formulation/device IP barriers are weak or expired, generics typically enter quickly, compressing prices.
• When delivery kinetics and device claims are protected, entrants face:
  • longer design-around cycles,
  • higher development costs,
  • and potential litigation.

Forecast impact

• Generic entry usually lowers:
  • gross margins (price erosion),
  • marketing spend efficiency (more promotional activity to maintain volume),
  • and average selling price.
• It can also expand volume if the product becomes meaningfully cheaper and accessible.

---

Clinical trial and market projection scenarios for nicotine (base, upside, downside)

Because nicotine “market” is delivery-form and geography-dependent, projections should be built as scenarios tied to cessation uptake and product channel economics.

Base case

• Modest growth driven by:
  • persistence in cessation policy,
  • incremental adoption of combination regimens,
  • stable OTC pharmacy distribution.
• Price pressure continues from generics in many markets, limiting margin expansion.

Upside case

• Faster uptake of rapid-acting NRT for craving control.
• Better adherence from improved user experience or combination packs.
• Increased reimbursement support for cessation programs, boosting patient conversion.

Downside case

• Regulatory or payer changes reduce access or require prior authorization for certain routes.
• Stronger competition from non-nicotine cessation pharmacotherapies or improved behavioral interventions.
• Faster generic substitution of differentiated delivery systems.

---

Key market metrics to track for nicotine forecasts (what changes the number the fastest)

• Adult smoking prevalence and quit attempt rates by geography.
• OTC vs prescription share in each major market.
• Combination regimen penetration (patch plus rapid-acting).
• Real-world adherence (days of use, discontinuation rates).
• Average selling price and promotional intensity by channel.
• Regulatory changes affecting labeling, advertising, or access.

---

Key Takeaways

• “Nicotine” market outlook is best assessed by delivery form and regulatory access, not by a single compound exclusivity timeline.
• Clinical development activity is concentrated on improving delivery kinetics, user adherence, and combination effectiveness, with endpoints tied to abstinence and craving relief.
• Patent and exclusivity barriers are formulation/device/method-of-use specific, so generic pressure and price erosion are usually driven by the strength (or absence) of those localized IP claims.
• Market projection depends on cessation policy uptake, OTC accessibility, combination regimen penetration, and channel pricing dynamics.

---

FAQs

1) Are there new nicotine NRT formulations in late-stage development?

Late-stage focus typically remains on delivery-kinetics and usability improvements for patch/gum/lozenge/inhaler/nasal spray rather than novel nicotine mechanisms.

2) What endpoints do nicotine cessation trials use for regulatory and payer relevance?

Trials commonly measure abstinence rates at fixed weeks and time-to-craving relief plus tolerability and adherence metrics.

3) How does combination NRT change market demand versus single-form products?

Combination regimens usually increase total nicotine product units per quitter and improve outcomes in clinical practice, supporting volume and often better pricing than single-form generic-heavy categories.

4) What drives price erosion in nicotine products?

Generic substitution after localized formulation/device IP expiration and broad OTC access increases competitive intensity and promotional discounting.

5) How does nicotine competition differ from non-nicotine cessation drugs?

NRT competition is mainly about access, tolerability, and craving-timing control, while non-nicotine drugs compete more directly on efficacy profile and adherence through different mechanisms.

---

References

No sources were provided in the prompt, and no web-enabled search or dataset access is available in this interface to cite specific trial registry entries, FDA product listings, or market-size figures.